ReviewFrontiers in cellular and infection microbiology2021
Testosterone in COVID-19: An Adversary Bane or Comrade Boon.
Review in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Trends and mortality due to acute respiratory distress syndrome in the United States (1999-2023): A 25-year nationwide study.Medicine · 2026Article
- Association of DHEAS levels with COVID19 severity, gender, age, comorbidities, and management strategies.Scientific reports · 2025Article
- Urine metabolomic analyses reveal metabolite disruptions in steroid hormone biosynthesis in monkeypox.iScience · 2025Article
- New insights on the potential effect of progesterone in Covid-19: Anti-inflammatory and immunosuppressive effects.Immunity, inflammation and disease · 2023Review
- SARS-CoV-2 infection and dysregulation of nuclear factor erythroid-2-related factor 2 (Nrf2) pathway.Cell stress & chaperones · 2023Review
- Changes in Reaction Time, Balance and Neuroplasticity after Exercise with a Face Mask in Male Adults with Mild COVID-19 Symptoms.Healthcare (Basel, Switzerland) · 2023Article
- Long COVID and risk of erectile dysfunction in recovered patients from mild to moderate COVID-19.Scientific reports · 2023Article
- SARS-CoV-2 infection and multi-organ system damage: A review.Biomolecules & biomedicine · 2023Review
- Psychophysical therapy and underlying neuroendocrine mechanisms for the rehabilitation of long COVID-19.Frontiers in endocrinology · 2023Review
- Identifying hub genes and common biological pathways between COVID-19 and benign prostatic hyperplasia by machine learning algorithms.Frontiers in immunology · 2023Article
- Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19.Pharmaceuticals (Basel, Switzerland) · 2022Article
- SARS-CoV-2 detection methods: A comprehensive review.Saudi journal of biological sciences · 2022Review
- Association between Brain Injury Markers and Testosterone in Critically-Ill COVID-19 Male Patients.Microorganisms · 2022Article
- Dynamic of Serum TWEAK Levels in Critically Ill COVID-19 Male Patients.Journal of clinical medicine · 2022Article
- Metabolic, Oxidative and Psychological Stress as Mediators of the Effect of COVID-19 on Male Infertility: A Literature Review.International journal of environmental research and public health · 2022Review
- Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.International immunopharmacology · 2022Review
- Blood transcriptome analysis revealed the crosstalk between COVID-19 and HIV.Frontiers in immunology · 2022Article
- Changes in the Blood Viscosity in Patients With SARS-CoV-2 Infection.Frontiers in medicine · 2022Review
- Clinical and Gene Features of SARS-CoV-2-Positive Recurrence in Patients Recovered From COVID-19.Frontiers in molecular biosciences · 2022Article
- Selinexor and COVID-19: The Neglected Warden.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a pandemic disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2), which leads to pulmonary manifestations like acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). In addition, COVID-19 may cause extra-pulmonary manifestation such as testicular injury. Both high and low levels of testosterone could affect the severity of COVID-19. Herein, there is substantial controversy regarding the potential role of testosterone in SARS-CoV-2 infection and COVID-19 severity. Therefore, the present study aimed to review and elucidate the assorted view of preponderance regarding the beneficial and harmful effects of testosterone in COVID-19. A related literature search in PubMed, Scopus, Web of Science, Google Scholar, and Science Direct was done. All published articles related to the role of testosterone and COVID-19 were included in this mini-review. The beneficial effects of testosterone in COVID-19 are through inhibition of pro-inflammatory cytokines, augmentation of anti-inflammatory cytokines, modulation of the immune response, attenuation of oxidative stress, and endothelial dysfunction. However, its harmful effects in COVID-19 are due to augmentation of transmembrane protease serine 2 (TMPRSS2), which is essential for cleaving and activating SARS-CoV-2 spike protein during acute SARS-CoV-2 infection. Most published studies illustrated that low testosterone levels are linked to COVID-19 severity. A low testosterone level in COVID-19 is mainly due to testicular injury, the primary source of testosterone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.